On November 14, 2016 Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, reported six data presentations at the 2016 EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) (ENA) Molecular Targets and Cancer Therapeutics Symposium in Munich, Germany (Press release, Ignyta, NOV 14, 2016, View Source [SID1234516588]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

One poster presentation will include updated clinical safety and efficacy data from the Phase 1b basket study of RXDX-105, the company’s VEGFR-sparing, potent RET inhibitor.

The company’s data that examine a novel combination of entrectinib — the company’s orally available, CNS-penetrant tyrosine kinase inhibitor targeting tumors that harbor TRK, ROS1 or ALK fusions — with trametinib, designed to overcome drug resistance to TRK inhibition, will be presented as a late-breaking oral plenary presentation.

The company also announced four additional poster presentations related to its robust pipeline of molecularly targeted oncology therapies — entrectinib, RXDX-105, and RXDX-106. These will be the first data Ignyta has disclosed for RXDX-106, and the data presented in the posters highlight both immuno-therapeutic and targeted activity of this novel agent.

"We are excited to provide updated clinical and preclinical data across multiple compounds from our cancer precision medicine pipeline," said Pratik Multani, M.D., Ignyta’s Chief Medical Officer. "In particular, the team is excited to present new clinical data on RXDX-105, and is honored that the ENA Scientific Program Committee has chosen entrectinib for an oral plenary presentation."

Details of the presentations are as follows:

Late-Breaking Oral Plenary Presentation:

Title:
Overcoming drug resistance to Trk inhibition by rational combination of entrectinib and trametinib: from bench to bedside (Abstract number 8LBA)
Presenter: Alexander Drilon, M.D., Memorial Sloan Kettering Cancer Center
Date/Time: Plenary Session 8: Exceptional Response and Expected Resistance

Friday, December 2, 2016, 10:30 am CET

Poster Presentations:

Entrectinib
Title:
Entrectinib, a highly potent pan-Trk, ROS1, and ALK inhibitor, has broad-spectrum, histology-agnostic anti-tumor activity in molecularly defined cancers (Abstract number 78, Poster number P049)
Date/Time: Tuesday, November 29, 2016, 11:45 am – 18:30 pm CET

RXDX-105
Title:
A phase 1/1b study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors (Abstract number 437, Poster number P116)
Date/Time: Thursday, December 1, 2016, 10:15 am – 17:00 pm CET

Title:
RXDX-105 demonstrates anti-tumor efficacy in multiple preclinical cancer models driven by molecular alterations in RET or BRAF oncogenes (Abstract number 85, Poster number P056)
Date/Time: Tuesday, November 29, 2016, 11:45 am – 18:30 pm CET

RXDX-106
Title:
Immuno-oncologic efficacy of RXDX-106, a selective, TAM family small molecule kinase inhibitor (Abstract number 65, Poster number P036)
Date/Time: Tuesday, November 29, 2016, 11:45 am – 18:30 pm CET

Title:
RXDX-106 is an orally-available, potent and selective TAM/MET inhibitor demonstrating preclinical efficacy in MET-dependent human malignancies (Abstract number 73, Poster number P044)
Date/Time: Tuesday, November 29, 2016, 11:45 am – 18:30 pm CET

A copy of the presentation and posters will be made available during the sessions in the Scientific Presentations section of the company’s website at View Source, and will be archived and available at that site.